Artimplant reports year end 2009 financial results

Artimplant (STO:ARTIB)

• Net revenue for the fourth quarter increased to SEK 5.8 million (4.6) and doubled for the full year to SEK 24.0 million (12.1)*
• The net loss for the fourth quarter improved to SEK 5.4 million (6.0) and for the full year the net loss improved to SEK 18.6 million (22.6)
• Earnings per share for the fourth quarter improved to SEK -0.09 (-0.10) and for the full year SEK -0.31 (-0.38)
• Product sales to end-customers and distributors multiplied to SEK 8.7 million (1.7) for the full year, equivalent to 37% (15) of product sales
• Sales of Artelon® Spacer for the fourth quarter amounted to SEK 2.4 million (3.1) and for the full year sales rose to SEK 13.1 million (7.4)
• Sales of Artelon® Tissue Reinforcement for the fourth quarter increased to SEK 3.3 million (1.6) and for the full year to SEK 10.2 million (4.1)
• Goal to reach positive cash flow before changes in working capital, at a monthly basis, towards the end of 2010
• The Board proposes that no dividend be paid for 2009

N.B. This is a translation from Swedish. The Swedish version shall always take precedence.

Artimplant will hold a telephone conference by reason of this report on February 11, 2010 at 11 am (CET). For further information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year

Source:

Artimplant

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.